CSIMarket
 


Atara Biotherapeutics Inc   (ATRA)
Other Ticker:  
 

Cumulative Atara Biotherapeutics Inc 's Working Capital Ratio for Trailing Twelve Months Period

ATRA's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

ATRA Working Capital Ratio for Trailing Twelve Months Period

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Growth 9.47 % 13.49 % -33.17 % -25.4 % -16.14 %
Y / Y Current Assets Growth -58.06 % -50.34 % -28.69 % -23.28 % -23.4 %
Working Capital Ratio for Trailing Twelve Months Period 2.7 3.32 4.04 3.89 3.85
Total Ranking # 1351 # 1152 # 1012 # 1222 # 1264
Seq. Current Liabilities Growth 6.09 % 9.84 % -13.99 % 9.24 % 9.98 %
Seq. Current Assets Growth -31.12 % -23.13 % -24.03 % 4.25 % -18.43 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2023
On the trailing twelve months basis Due to rise in Current Liabilities in the III. Quarter to $79 millions, average cumulative Working Capital Ratio for Trailing Twelve Months Period decreased to 2.7 below Atara Biotherapeutics Inc average Working Capital Ratio for Trailing Twelve Months Period.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Biotechnology & Pharmaceuticals industry 136 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Atara Biotherapeutics Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about ATRA
Working Capital Ratio ATRA in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 137
Sector # 794
S&P 500 # 2294


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
23.46 8.95 2.7
(Jun 30 2017)   (Sep 30 2023)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2023, within Biotechnology & Pharmaceuticals Industry Working Capital Ratio for Trailing Twelve Months Period
Editas Medicine Inc   7.35 
Compugen Ltd  7.23 
Vir Biotechnology Inc   7.15 
Prime Medicine Inc   6.98 
Renovacor Inc   6.79 
Kodiak Sciences Inc   6.72 
Senti Biosciences Inc   6.70 
Surface Oncology Inc   6.65 
Bioatla Inc   6.60 
C4 Therapeutics Inc   6.60 
Polarityte Inc   6.52 
Halozyme Therapeutics Inc   6.44 
Palisade Bio Inc   6.38 
In8bio Inc   6.34 
Adma Biologics Inc   6.33 
Cardiol Therapeutics inc   6.27 
Twist Bioscience Corporation  6.26 
Fennec Pharmaceuticals Inc   6.26 
Dyadic International Inc  6.01 
Fate Therapeutics Inc   5.90 
Ocugen Inc   5.89 
Zura Bio Limited  5.70 
Denali Therapeutics Inc   5.64 
Sutro Biopharma Inc   5.62 
Miromatrix Medical inc   5.56 
Sophia Genetics Sa  5.51 
Turnstone Biologics Corp   5.51 
Biocryst Pharmaceuticals Inc   5.49 
X4 Pharmaceuticals Inc  5.42 
Omega Therapeutics Inc   5.41 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com